This study aimed to develop and validate a combined nomogram model based on superb microvascular imaging (SMI)-based deep learning (DL), radiomics characteristics, and clinical factors for noninvasive differentiation between immunoglobulin A nephropathy (IgAN) and non-IgAN.We prospectively enrolled patients with chronic kidney disease who underwent renal biopsy from May 2022 to December 2022 and performed an ultrasound and SMI the day before renal biopsy. The selected patients were randomly divided into training and testing cohorts in a 7:3 ratio. We extracted DL and radiometric features from the two-dimensional ultrasound and SMI images. A combined nomograph model was developed by combining the predictive probability of DL with clinical factors using multivariate logistic regression analysis. The proposed model's utility was evaluated using receiver operating characteristics, calibration, and decision curve analysis. In this study, 120 patients with primary glomerular disease were included, including 84 in the training and 36 in the test cohorts. In the testing cohort, the ROC of the radiomics model was 0.816 (95% CI:0.663-0.968), and the ROC of the DL model was 0.844 (95% CI:0.717-0.971). The nomogram model combined with independent clinical risk factors (IgA and hematuria) showed strong discrimination, with an ROC of 0.884 (95% CI:0.773-0.996) in the testing cohort. Decision curve analysis verified the clinical practicability of the combined nomogram. The combined nomogram model based on SMI can accurately and noninvasively distinguish IgAN from non-IgAN and help physicians make clearer patient treatment plans.
Keywords: IgA nephropathy; deep learning; radiomics; superb microvascular imaging; ultrasound.